Patiromer Sorbitex Calcium

CHEMBL5315081 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A sorbitex calcium formulation of patiromer used as the commercially available oral treatment for hyperkalemia, sharing the same mechanism and indications as patiromer calcium. The sorbitex component is the polymer carrier that binds potassium in the gut.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

A sorbitex calcium formulation of patiromer used as the commercially available oral treatment for hyperkalemia, sharing the same mechanism and indications as patiromer calcium. The sorbitex component is the polymer carrier that binds potassium in the gut.

Yes, Patiromer Sorbitex Calcium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5315081. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Patiromer Sorbitex Calcium PillFYIで

クイックデータ

外部リンク

ChEMBL CHEMBL5315081

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.